NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced four abstracts accepted for presentation at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. The abstracts represent initial results of ongoing collaborations with Flatiron’s research and academic partners.
The research to be presented includes a retrospective observational study with the Food & Drug Administration — the first findings from the collaboration announced in 2016. Initial results from Foundation Medicine and Flatiron’s Clinico Genomic Database project will also be shown as a part of a poster discussion presentation. Finally, Yale and Flatiron partnered on two studies examining racial, age and insurance disparities in cancer care. The presentation schedule and links to abstracts can be found below.
- Rates of PD-L1 expression testing in US community-based oncology practices for patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab or pembrolizumab (Abstract #11596; Poster #296)
Presenting Author: Sean Khozin, MD, MPH, U.S. Food and Drug
Date/Time: Saturday, June 3 — 1:15PM - 4:45PM CDT
Session: Tumor Biology
- Racial disparities in the use of programmed death 1 (PD-1) checkpoint inhibitors (Abstract 3068; Poster #163)
Presenting Author: Jeremy O'Connor, MD, Yale School of Medicine
Date/Time: Monday, June 5 — 8:00AM-11:30AM CDT
Session: Developmental Therapeutics - Immunotherapy
- Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer (Abstract #6563; Poster #385)
Presenting Author: Carolyn Jean Presley, MD, Yale Cancer Center
Date/Time: Monday, June 5 — 1:15 PM - 4:45 PM CDT
Session: Health Services Research, Clinical Informatics, and Quality of Care
Poster Discussion Presentation
- Development and validation of a real-world clinico-genomic database (Abstract #2514; Poster #6)
Presenting Author: Gaurav Singal, MD, Foundation Medicine, Inc.
Date/Time: Monday, June 5 — 11:30AM - 12:45PM CDT (Arie Crown Theater)
Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
A complete list of Flatiron's accepted abstracts can be found here. To learn more about Flatiron Health, visit our booth during the conference at #4031.
ABOUT FLATIRON HEALTH
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 265 community cancer clinics, three major academic research centers and 11 out of the top 13 therapeutic oncology companies. Flatiron is backed by Google Ventures, First Round Capital, Roche and others. For more information, please visit www.flatiron.com or follow us @FlatironHealth.